Apellis (APLS) tendered 82.4% of shares; Biogen to close merger May 14, 2026
Apellis Pharmaceuticals has successfully concluded its tender offer, with approximately 82.4% of its outstanding shares tendered, allowing Biogen to proceed with the acquisition. The merger is expected to close on May 14, 2026, without a stockholder vote, and Apellis will become a wholly-owned subsidiary of Biogen, leading to its delisting from Nasdaq. Shareholders will receive $41.00 per share in cash plus a contingent value right up to $4.00 per share.
How this was made
The 30-second read
Why it matters
The completion of the tender offer and upcoming merger are likely to influence investor sentiment positively, especially within the biotech sector.
Market read
The merger is a notable event within the biotech industry, with potential ripple effects on related stocks and sectors.
What to watch
Potential regulatory hurdles or shareholder dissent that could delay or alter merger terms, affecting stock performance.
Background
Apellis Pharmaceuticals has been involved in strategic growth through mergers and acquisitions, with this recent tender offer marking a significant milestone.
Ticker impact
Primary focus due to recent merger activity.
Moderate upward movement post-merger completion, with potential short-term volatility around the closing date.
The tender acceptance rate and announced merger terms provide clear indications of the deal's progression and valuation, reducing uncertainty.
Market effects
Potential positive sentiment for biotech and pharmaceutical merger activities.
Limited; primarily affects the biotech sector within the US.
Low; regional focus with minimal immediate global impact.
Counterpoint
Some analysts may view the merger as overvalued or expect integration challenges, which could negatively impact the stock post-merger.
Key entities
- CompanyApellis Pharmaceuticals
A biotech company specializing in ophthalmology and immunology therapies.
- CompanyBiogen
A global biotech firm focusing on neurological and neurodegenerative diseases.
